Lv11
70 积分 2024-08-15 加入
Decoding BRCA1 and BRCA2 mutations: implications of mutation type and domain location for PARP inhibitor response in ovarian cancer
4小时前
求助中
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
1个月前
已完结
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
1个月前
已完结
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
1个月前
已完结
The Forefront of Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer in China: A Review of Updated Evidence With PARP Inhibitors
1个月前
已完结
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
1个月前
已完结
Ovarian Cancer: A Review
3个月前
已完结
Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability
3个月前
已完结
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
5个月前
已完结
皖公网安备34019202002308
